CAS 1428333-96-3|Pritelivir mesylate
Introduction：Basic information about CAS 1428333-96-3|Pritelivir mesylate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Pritelivir mesylate | ||
|---|---|---|---|
| CAS Number | 1428333-96-3 | Molecular Weight | 498.6 |
| Density | / | Boiling Point | / |
| Molecular Formula | C19H22N4O6S3 | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | BAY57-1293 mesylate |
|---|
Pritelivir mesylate BiologicalActivity
| Description | Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>HSVResearch Areas >>Infection |
| Target | IC50: 0.02 μM (HSV1-2)[1] |
| In Vivo | Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase–primase enzyme complex[2]. Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis[3]. Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS[3]. Animal Model: Female BALB/c mice[3] Dosage: 0.03 to 45 mg/kg Administration: Administered orally, twice daily at approximately 12 h intervals, for 7 days Result: Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%. |
| References | [1]. Ligat G, et al. Identification of Amino Acids Essential for Viral Replication in the HCMV Helicase-PrimaseComplex. Front Microbiol. 2018 Oct 23;9:2483. [2]. Wald A, et al. Helicase-primase inhibitor Pritelivir for HSV-2 infection. N Engl J Med. 2014 Jan 16;370(3):201-10. [3]. Quenelle DC, et al. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis. Antiviral Res. 2018 Jan;149:1-6. |
Chemical & Physical Properties
| Molecular Formula | C19H22N4O6S3 |
|---|---|
| Molecular Weight | 498.6 |
| InChIKey | PPAJHCGEURRDOG-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)O.Cc1nc(N(C)C(=O)Cc2ccc(-c3ccccn3)cc2)sc1S(N)(=O)=O |
